Internationalization of regulatory requirements

Area of Science:

• Regulatory Affairs
• Pharmaceutical Policy

Background:

• Harmonisation of medicines regulatory requirements aims to expedite patient access to novel therapeutics and minimize redundant animal and human testing.
• European Union (EU) harmonisation is complete, enabling single-submission dossiers for European marketing authorizations, supported by EU efficacy guidelines.

Purpose of the Study:

• To outline the evolution and impact of medicines regulatory harmonisation, particularly through the International Conference on Harmonisation (ICH).
• To highlight the significance of the Common Technical Document (CTD) in standardizing drug application formats across major regions.

Main Methods:

• Review of regulatory harmonisation efforts within the EU and internationally.
• Analysis of the development and implementation of International Conference on Harmonisation (ICH) guidelines and the Common Technical Document (CTD).

Main Results:

• Over 40 guidelines have been harmonised among the EU, Japan, and the USA via the ICH.
• The Common Technical Document (CTD) provides a common format for drug applications in these key regions.
• The CTD's implementation in July 2003 is expected to significantly influence review processes and information exchange.

Conclusions:

• Medicines regulatory harmonisation, exemplified by the ICH and CTD, streamlines drug approval processes.
• The CTD represents a significant advancement in global pharmaceutical regulatory cooperation.
• Successful harmonisation enhances efficiency and facilitates the global availability of new medicines.